The app that went viral for predicting your death date has a new pitch: What if you could buy more time?
Most Days, Inc., the startup behind Death Clock, launched Life Lab this February—an AI-powered health concierge layered directly into the app that made calculating your mortality oddly addictive. Starting at $99 a year, Life Lab connects users to nationwide blood testing through Labcorp, Quest, and BioReference, then analyzes biomarkers to, in theory, help extend the lifespan the app first quantified.
It's a sharp pivot. Death Clock built its audience on morbid curiosity. More than a million downloads across 100-plus countries as of February 2026, tens of thousands of them now paying customers. That's a captive market for an upsell, particularly one promising to push back the very expiration date users logged in to discover.
Whether people will actually pay repeatedly for AI-generated longevity advice—and whether that advice works—remains the bet.
The Gap Between Now and Later
Life Lab retains Death Clock's original hook: a 29-question assessment, maybe three minutes of your time, that spits out a predicted death date. The AI, trained on what the company claims is more than 1,200 longevity studies, hasn't softened. It still tells you when it thinks you'll die.
Now it adds a second number. A "potential" death date, achievable through optimized health. Life Lab exists to close that gap.
Users receive what Most Days calls a Longevity Report—screening recommendations, clinical guidance on medications and supplements, behavioral audits. The system tracks biomarkers over time, updating life expectancy projections as new data flows in. You can complete labs at partner sites (the company lists access through 4,200 locations across 49 states) or upload existing physician records. The AI parses both.
The biomarker menu runs deep. Pricing tiers unlock different panels, but the platform monitors progressive markers like ApoB and HbA1c alongside standard lipid panels, inflammation indicators such as hs-CRP, metabolic measures including fasting insulin and cystatin C with eGFR, hormones—testosterone, estradiol, thyroid—and vitamins. The top-tier Advanced plan at $299 annually promises 26 specific biomarkers.
Most Days describes Life Lab as "a living system that evolves with your habits and bloodwork to grow your life expectancy in real-time." Classic Silicon Valley phrasing: dynamic, data-driven, perpetually optimized. The clinical board includes Dr. Tyler Johnson as chairman, alongside Dr. Marilyn Tan and Dr. Todd Dorfman, though how closely the AI hews to clinical judgment versus algorithmic pattern-matching isn't entirely clear.
Undercutting the Competition
Death Clock's pricing strategy is aggressive. At $99 for the entry-level Baseline tier, it costs less than a single visit to many concierge doctors. Function Health, which dropped its annual price from $499 to $365 last November, offers 100-plus biomarkers through Quest at nearly four times Death Clock's starting rate. Lifeforce typically runs around $149 monthly plus a $349 enrollment fee. InsideTracker's Ultimate test alone can exceed $600.
Life Lab's three-tier structure—Baseline at $99, Foundation at $199, Advanced at $299—gives users pricing flexibility while maintaining significant savings against established players. The trade-off? There's no white-glove concierge service, no quarterly physician consults bundled in. You get AI analysis, biomarker tracking, actionable recommendations. Automation replacing the human touch that justifies higher price points elsewhere.
For health-conscious consumers who don't need—or don't want—intensive clinical handholding, that might be enough.
Navigating Regulated Waters
Life Lab wades into heavily regulated territory. Blood testing requires partnerships with established labs, HIPAA compliance, careful handling of consumer health data. Death Clock's Consumer Health Data Privacy Policy, last updated August 6, 2025, states the company does not share health-related personal information with advertising partners. The platform uses generative AI service providers—Google Gemini and OpenAI—under agreements that allegedly prohibit training on user data.
A separate HIPAA Authorization form allows Vital and BioReference Laboratories to release lab and telehealth information to Death Clock, with standard revocation and re-disclosure terms. The Consumer Health Data Privacy Policy details rights to access, delete, and withdraw consent, framing processors like ChatGPT and AWS as bound to permitted uses only.
Privacy policies from mid-2025 in a fast-moving regulatory environment warrant scrutiny, perhaps more than Most Days would prefer. State consumer health data laws continue evolving, and any recent changes won't be reflected in documentation from that period.
Founder Brent Franson brings operational experience—he previously led Euclid Analytics before WeWork acquired the spatial analytics company in early 2019. Most Days raised a $3.2 million seed round in December 2020, led by Freestyle Capital, Harrison Metal, and Village Global, with backing from health-sector operators including Owen Tripp of Included Health, Noah Lang of Stride Health, and former CrossFit CEO Eric Roza. Recent press materials reiterate support from Freestyle, Village Global, Harrison Metal, King River, and Origin Ventures, though the company hasn't disclosed subsequent funding.
The company's headcount, at least as of recent third-party estimates, sits somewhere between 11 and 50 employees. Whether that's grown with the Life Lab launch isn't public.
The Longevity Tech Pivot
Death Clock's move illustrates a broader shift in consumer health. Apps that began as engagement plays—tracking steps, monitoring sleep, predicting lifespan—are layering in clinical infrastructure. The goal is recurring revenue through subscriptions, not one-time curiosity downloads.
Life Lab positions itself as "Medicine 3.0" for the mass market, borrowing terminology popularized by longevity physician Peter Attia. Whether AI-driven biomarker analysis at $99 annually can replicate outcomes from higher-touch programs remains unproven. Function Health, despite its price cut, still costs nearly four times Death Clock's entry tier. Lifeforce and similar services charge multiples more.
The competitive landscape will test whether consumers prioritize cost, comprehensiveness, or clinical oversight. Death Clock is betting that enough people want accessible, affordable longevity optimization—and that an AI trained on more than a thousand studies can deliver value without expensive human clinicians in the loop.
It's a gamble, really. The audience morbidly curious about their death date might be willing to pay, repeatedly, for strategies to postpone it. Or they might scroll past the upsell and go back to refreshing their countdown timer, watching the seconds tick away.
For Most Days, the question isn't just whether Life Lab works. It's whether customers believe it does—enough to subscribe, year after year, chasing a date they'll never see coming anyway.
